BiotechTube

Regadenoson + gadofoveset trisodium

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myocardial Ischemia

Conditions

Myocardial Ischemia

Trial Timeline

Sep 1, 2012 → Feb 1, 2014

NCT ID
NCT01655043

About Regadenoson + gadofoveset trisodium

Regadenoson + gadofoveset trisodium is a phase 2 stage product being developed by Astellas Pharma for Myocardial Ischemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01655043. Target conditions include Myocardial Ischemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01655043Phase 2Completed

Competing Products

20 competing products in Myocardial Ischemia

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
76
AbciximabEli LillyApproved
85
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
77
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
23
No interventionAstellas PharmaPre-clinical
23
Empagliflozin + PlaceboEli LillyPhase 3
77
Abciximab + Abciximab placeboEli LillyPhase 3
77
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
77
AbciximabEli LillyApproved
85
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
77
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
77
abciximabEli LillyApproved
85
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
65
Thrombolytic therapyEli LillyPre-clinical
23
TicagrelorAstraZenecaPre-clinical
23
TicagrelorAstraZenecaPhase 2
52
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
23
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
33
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
77
RosuvastatinAstraZenecaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85